ストックスクリーナーアプリを入手
8.82
1.50%
0.13
アフターアワーズ：
8.84
0.02
+0.23%
Design Therapeutics Inc (DSGN) 最新ニュース
What analysts say about Design Therapeutics Inc stockMarket Sentiment Shifts & Breakthrough Stock Performance - earlytimes.in
2026 world cup analysis predictions: How sustainable is Design Therapeutics Inc. stock dividend payout2026 world cup usa national team round of 16 defensive leaders build up play tactical prediction statistical analysis - Улправда
Wall Street Zen Upgrades Design Therapeutics (NASDAQ:DSGN) to "Hold" - MarketBeat
Design Therapeutics Inc Stock Analysis and ForecastTrading Psychology Tips & Free Discover Breakout Stocks Early - earlytimes.in
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why - Defense World
Design Therapeutics Inc (NASDAQ:DSGN) Nasdaq Index Genetic Focus - Kalkine Media
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5%What's Next? - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Nasdaq Futures Neurology Programs - Kalkine Media
Risk Analysis: Is Design Therapeutics Inc stock dividend yield sustainableEarnings Recap Summary & Real-Time Price Movement Reports - moha.gov.vn
How sustainable is Design Therapeutics Inc. stock dividend payoutWatch List & Pattern Based Trade Signal System - Улправда
Investment Report: Will Ingredion Incorporated stock benefit from green energy trendsJuly 2025 Closing Moves & Detailed Earnings Play Strategies - moha.gov.vn
Design Therapeutics Shares Gain Momentum on Clinical Progress - AD HOC NEWS
➡️ Break above $200 with volume bullish continuationBreakout Stock Watch & Free Stock Trading Signal Access - Bollywood Helpline
Weekly Earnings: Is Design Therapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Community Consensus Stock Picks - Улправда
Why Design Therapeutics Inc. stock is rated strong buy2025 Price Action Summary & Technical Pattern Based Signals - Улправда
Why Design Therapeutics Inc. stock appeals to analystsJuly 2025 Breakouts & AI Driven Price Forecasts - Улправда
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Is Design Therapeutics Inc. stock a good choice for value investorsSwing Trade & Risk Managed Investment Signals - Улправда
Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia - MSN
Design Therapeutics upgraded to Outperform from Market Perform at Leerink - MSN
Can Design Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Short Interest & Expert Curated Trade Setups - Улправда
Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design - Business Wire
Design Therapeutics Earnings Notes - Trefis
Design Therapeutics (DSGN) details 295,312 performance option shares vested - Stock Titan
BlossomHill Therapeutics Announces $84 Million Financing to - GlobeNewswire
Design Therapeutics (NASDAQ:DSGN) Stock Price Down 5.8%Time to Sell? - MarketBeat
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $14.00 - Defense World
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why retail investors pile into Design Therapeutics Inc. stockJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress By Investing.com - Investing.com South Africa
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7 - MarketScreener
Will Design Therapeutics Inc. stock deliver shareholder valueWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Design Therapeutics (DSGN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Yahoo Finance
How Design Therapeutics Inc. stock performs in weak economyNew Guidance & Safe Entry Point Alerts - Newser
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Design Therapeutics (NASDAQ:DSGN) Trading Up 9%What's Next? - MarketBeat
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):